SHAREHOLDER ALERT: QFIN AHCO SAVA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / September 9, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
360 DigiTech, Inc. (NASDAQ:QFIN)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/360-digitech-inc-loss-submission-form?prid=19418&wire=1
Lead Plaintiff Deadline: September 13, 2021
Class Period: April 29, 2021 - July 7, 2021
Allegations against QFIN include that: (i) the Company had been collecting personal information in violation of relevant People's Republic of China laws and regulations; (ii) accordingly, 360 DigiTech was exposed to an increased risk of regulatory scrutiny and/or enforcement action; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. (NASDAQ:AHCO)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/adapthealth-corp-f-k-a-dfb-healthcare-acquisitions-corp-loss-submission-form?prid=19418&wire=1
Lead Plaintiff Deadline: September 27, 2021
Class Period: November 11, 2019 - July 16, 2021
Allegations against AHCO include that: (i) AdaptHealth had misrepresented its organic growth trajectory by retroactively inflating past organic growth numbers without disclosing the changes, in violation of Securities and Exchange Commission regulations; (ii) accordingly, the Company had materially overstated its financial prospects; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Cassava Sciences, Inc. (NASDAQ:SAVA)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19418&wire=1
Lead Plaintiff Deadline: October 26, 2021
Class Period: February 2, 2021 - August 24, 2021
Allegations against SAVA include that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
© 2021 Accesswire. All Rights Reserved.